Medexus Pharma USA is a wholly owned subsidiary of Medexus Pharmaceuticals, Inc. Based in Chicago, Illinois, Medexus Pharma USA focuses on the development and commercialization of novel treatments for autoimmune diseases, oncology, and other near market opportunities.
The company leverages its core capabilities in development, operations, and commercialization, its business development efforts, as well as numerous partnerships to create opportunities for significant medical advancements to help improve patients’ lives.
Medexus Pharma USA develops mid-to-late stage molecules, drug dosage forms, concentrations, and modes of delivery that have the potential to improve the efficiency and effectiveness of existing medicines.
The company’s personalized approach to medicine is driven by the idea that patients should have the ability to manage their own therapies and have access to greater treatment options.
Medexus Pharmaceuticals Inc. is a leading innovative and rare disease pharmaceutical company with a focus on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases.About Us
Our growing portfolio includes promoted products Rasuvo and IXINITY, and our late-stage pipeline in the US includes triamcinolone hexacetonide and treosulfan.View Product Portfolio
Medexus Pharma, Inc. is committed to creating a culture that encourages responsible corporate action at every level of our organization. We strive for the highest standards of business conduct and ethics.
Our Code of Conduct and Business Ethics illustrates the guiding ethical principles that support our commitment to compliance. Every day, we are faced with decisions and actions that give us the opportunity to embody the principles of our Code of Conduct. We are committed to maintaining an effective Compliance Program in accordance with federal and state government laws, regulations, and guidelines. We continually develop and implement policies, programs, and training activities to shape behaviors and help us achieve our compliance goals.
As part of the Medexus Pharma, Inc. continuing commitment to corporate compliance, Medexus Pharma, Inc. declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Policy as mandated by this California law. To the best of our knowledge, as of October 16, 2013, Medexus Pharma, Inc. is in substantial compliance with its Comprehensive Compliance Policy and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
For a copy of our Comprehensive Compliance Policy, you may request a copy via our contact us form or by calling 1-855-336-3322.
This is a list of Authorized Distributors of Record (“ADRs”) with whom Medexus Pharma has an ongoing relationship to distribute Medexus Pharma products in the United States.
For adverse events, medical inquiries, and product related concerns, please call 1-855-336-3322.
Medexus is committed to supporting the medical community through a variety of initiatives that enhance patient care in areas of unmet medical need.
For information regarding Investigator Initiated Trials (IITs), Independent Medical Education grants (IME) and Sponsorships, and how to request support, please click here.
29 N Wacker
Chicago, IL 60606